These findings could significantly improve our understanding of the cause and underlying molecular events in pancreatic cancer, these promising molecular markers identified that gene expression profiling studies including MET, MELK, SDC1, THBS1 and TOP2A and pathways could be new effective therapeutic targets for pancreatic cancer. This evidence concerns the gene MELK and familial pancreatic carcinoma.